Apollo Endosurgery, Inc. (NASDAQ:APEN) Files An 8-K Results of Operations and Financial Condition

Apollo Endosurgery, Inc. (NASDAQ:APEN) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02 Results of Operations and Financial Condition.

On May 4, 2017, Apollo Endosurgery, Inc. (the “Company”) issued a
press release reporting its financial results for the fiscal
quarter ended March 31, 2017. A copy of the Companys press
release is attached hereto as Exhibit 99.1.
The press release attached hereto as Exhibit 99.1, is furnished
and shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the
Securities Act of 1933, as amended. The information contained
herein and in the accompanying Exhibit 99.1 shall not be
incorporated by reference into any filing with the Securities and
Exchange Commission made by the Company, whether made before or
after the date hereof, regardless of any general incorporation
language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description of Document
99.1
Press release, issued by Apollo Endosurgery, Inc.,
dated May 4, 2017.


About Apollo Endosurgery, Inc. (NASDAQ:APEN)

Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company’s products include ORBERA, LAP-BAND and OverStitch. The Company’s product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract.

Apollo Endosurgery, Inc. (NASDAQ:APEN) Recent Trading Information

Apollo Endosurgery, Inc. (NASDAQ:APEN) closed its last trading session up +0.48 at 6.98 with 11,936 shares trading hands.

An ad to help with our costs